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Abstract
Women remain underrepresented in HIV research. The AIDS Clinical Trials Group (ACTG) 5366 study was
the first HIV cure-related trial conducted exclusively in women. Our multidisciplinary team integrated
participant-centered reports into the ACTG 5366 protocol to elicit their perspectives. We nested mixed-
methods surveys at the enrollment and final study visits to assess ACTG 5366 participants’ perceptions and
experiences. Of 31 participants enrolled in the ACTG 5366, 29 study agreed to complete the entry ques-
tionnaire and 27 completed the exit survey. The majority of study participants were nonwhite. We identified
societal and personal motivators for participation, understanding of risks and benefits, and minor miscon-
ceptions among some trial participants. Stigma was pervasive for several women who joined the study, and
served as a motivator for study participation. Reimbursements to defray costs of study participation were
reported to facilitate involvement in the trial by about one-third of participants. Almost all respondents
reported positive experiences participating in the ACTG 5366 trial. The ACTG 5366 study showed that it is
possible to recruit and retain women in HIV cure-related research and to embed participant-centered out-
comes at strategic time points during the study. The findings could help in the design, implementation,
recruitment, and retention of women in HIV cure-related research and highlight the value of assessing
psychosocial factors in HIV cure-related research participation.
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Introduction
Despite bearing a significant burden of the HIV epi-demic,1,2 women remain chronically underrepresented in
HIV research.3,4 In a landscape analysis of HIV cure-related
research, women accounted for 17.3% of participants in hu-
man trials conducted through 2017.5 A systematic review of
104 HIV cure-related studies published between 1995 and
2012 showed that women represented a median of 11.1%
participants in these studies.3 In a second review of 151
publications on HIV cure-related clinical studies between
1995 and 2003, only 6% disaggregated analyses by sex/gender
variables.6 The low representation of women is concerning in
light of data suggesting important differences in immunologic
and virologic factors between women and men.7–12
Sex differences have been demonstrated in viral reservoir
dynamics10 and sex hormones appear to mediate mechanisms
of latency maintenance and reversal.13 In addition to bio-
logical differences, sociobehavioral factors (e.g., access to
care, adherence to antiretroviral therapy (ART), stigma,
disempowerment, and marginalization) affect clinical out-
comes.6 Understanding how these biological and socio-
behavioral differences affect HIV cure-related research
efforts will be critical in ensuring that interventions are safe
and effective in both women and men.
The AIDS Clinical Trials Group (ACTG) 5366 study
(‘‘Selective Estrogen Receptor Modulators to Enhance the
Efficacy of Viral Reactivation with Histone Deacetylate In-
hibitors’’) [NCT03382834] was the first HIV cure-related
trial conducted exclusively in women.14 This randomized,
open-label latency-reversal trial assessed the effects of ta-
moxifen exposure in combination with vorinostat, compared
to vorinostat alone, on viral reactivation among postmeno-
pausal cisgender women living with HIV who were virally
suppressed on ART in the United States. The trial enrolled 31
women living with HIV (21 in the tamoxifen + vorinostat
arm, and 10 in the vorinostat alone arm).
Furthermore, very few data exist regarding participant
experiences within HIV cure trials. We and others have ad-
vocated for strategically embedding assessments of partici-
pant experiences into ongoing HIV cure trials to improve
recruitment, informed consent, and retention of study par-
ticipants.15–17 While such work is emerging,18,19 to date, few
trials have included participant reports in the United States,20
and none has focused on women. With a multidisciplinary
team of sociobehavioral scientists, HIV patient advocates and
community members, bioethicists, biomedical HIV cure re-
searchers, HIV care providers, and psychologists, we inte-
grated participant-centered reports into the ACTG 5366
protocol to elicit motivations, perceptions, and experiences
of women in the trial. The main objective of the social sci-
ences component of the ACTG 5366 protocol was to deter-
mine how women enrolled in the study perceived and
experienced the trial. In this study, we report data from sur-
veys administered at study enrollment and exit. To ensure
proper de-identification of the participant who completed
responses in Spanish, her results are presented in English.
Methods
Nested, mixed-methods surveys assessing ACTG 5366
participants’ perceptions and experiences were administered at
the enrollment visit and at the final study visit. The enrollment
visit took place *1 month after screening evaluations and
coincided with the start of protocol interventions (i.e.,
vorinostat – tamoxifen). The exit survey took place around 65
days after study entry. Surveys were administered online using
Qualtrics (Provo, UT) from June to December 2018. Partici-
pants were given the option to decline survey completion. In
exchange for their time, participants received $25 for entry
survey completion and $15 for exit survey completion, in
addition to receiving compensation for their time related to
participation in the clinical portion of the trial according to the
Institutional Review Board (IRB)-approved informed consent
form and local clinical research site (CRS) procedures. The
study was conducted at 15 US-based CRS in the ACTG net-
work and all participating sites received standardized survey
administration training before study initiation.
Survey items were developed in collaboration with the
community representatives (K.S. and D.E.), and the ACTG
5366 study protocol specialist (L.H.), along with input from
the ACTG 5366 protocol team. Surveys were translated by a
professional Spanish translator without back-translation to
English. Women with limited literacy were offered assistance
in reading and recording responses. The study was approved
by the IRB from each participating CRS and separately ap-
proved by the UNC Non-Biomedical IRB.
The entry survey covered the following domains: demo-
graphic and self-perceived health status characteristics, atti-
tudes toward HIV cure-related research, motivations driving
decisions to participate in the ACTG 5366 study, scientific
understanding of the study, perceptions of risks and benefits,
meaning of study participation, role of self-image and stigma,
and role of study compensation. The exit survey covered
overall experience in the study, decisional regrets, and rec-
ommendations to improve the study and future similar
studies. Response options included yes/no/don’t know,
true/false, multiple choice, and slide-bar questions. Surveys
also contained ‘‘specify’’ and ‘‘please explain’’ questions, as
well as open-ended free-text questions intended to solicit
short responses. We pilot tested the ACTG 5366 social sci-
ences surveys in collaboration with participating CRS and the
community representatives (K.S. and D.E.), and made revi-
sions to the instruments before study start. We did not con-
duct formal cognitive testing.
We chose a convergent mixed-method design and gave
equal weight to both quantitative and qualitative responses.21
Given the small sample size, we analyzed quantitative data
descriptively, providing frequencies of responses aggregated
across all ACTG 5366 sites without bivariate or multivariate
analyses. Due to the sensitive nature of the data and the small
enrollment, site-specific data are not reported. For semi-
structured and open-ended questions, we conducted con-
ventional content analysis to systematically organize text
units into a structured format. We did not use a preexisting
coding scheme. Due to the small number of responses and
brevity of text units, the lead author organized emergent
themes in a Microsoft Word processing document. For each
question, similar responses were clustered into key themes.
A research assistant reviewed the participants’ responses and
confirmed the themes that initially emerged. Here, we pro-
vide quotations that were broadly representative of the key
themes that transpired in the survey responses. We first report




Demographic and health characteristics of respon-
dents. Of the 31 women enrolled in the ACTG 5366 study,
29 (93.5%) agreed to complete the entry survey (28 in En-
glish and 1 in Spanish). Of those who completed the entry
survey, 18 were black/African American, 10 were white, and
1 was American Indian/Alaskan Native. Seven had less than
high school education, and 18 had a yearly household income
of less than $25,000, 14 relied on some form of government
support to cover basic living and other expenses (Table 1).
We asked ACTG 5366 study participants to assess their
own health status at the entry visit using a scale of 0% (poor)
to 100% (best imaginable). Of the 26 women who answered
this question, only one scored below 80%, and all others
reported a score >80% denoting self-perceived good health
(Fig. 1).
Attitudes toward HIV cure research at study entry
Meaning of an HIV cure. At the entry visit, ACTG 5366
study participants were asked to describe what an HIV cure
would mean to them. Of the 29 respondents, 8 stated that
HIV cure would mean not having to take HIV medications
(e.g., ‘‘my life with no meds,’’ ‘‘no longer have to take any
medications for HIV,’’ ‘‘never taking medicine’’). Fur-
thermore, six women equated a cure with freedom, hope,
empowerment, life, and living without fear (e.g., ‘‘it means
liberation from HIV stigma and a revolution of medical
proportion,’’ ‘‘it means hope to be cured from this virus,’’
‘‘hope for HIV patients,’’ ‘‘life’’), and five referenced
having HIV completely eliminated from the body. Addi-
tional responses included ‘‘better immune system,’’ ‘‘that I
would be healthier,’’ ‘‘so that I don’t have to go to the doctor
all the time,’’ among others.
Meaning of HIV cure-related research and experience with
research participation. When asked to describe what HIV
cure-related research meant to them, nine women indicated
that research meant getting closer to the possibility of cure
(e.g., ‘‘means we are getting closer to a real cure,’’ ‘‘it means
that they [researchers] will find a cure [for] people that are
living with the virus through research’’). Eight stated that
HIV cure-related research meant helping other people living
with HIV, including dealing with stigma (e.g., ‘‘finding a
cure to help people not to be stigmatized,’’ ‘‘helping others
not having to live with a disease that is so stigmatized by
society,’’ ‘‘to help others, to help future generations’’). Two
made reference to improvements in HIV therapeutics, and
other respondents saw the opportunity to be able to make a
difference.
In terms of previous participation in research, 22/29 wo-
men were new to HIV cure-related research participation, 5/
29 had prior HIV cure-related research experience, and 2/29
did not know if they had previously participated in an HIV
cure-related study. Only about half (15/29) of the women had
previously participated in an HIV-treatment study, including
other ACTG HIV observational and treatment studies. All
women (29/29) indicated general interest in HIV cure-related
research.
Greatest potential benefits. In terms of the possible
benefits of a future HIV cure/remission strategy that would
most positively affect the lives of ACTG 5366 study partic-
ipants, the five most frequent answers were the following: (1)
having HIV completely eliminated from the body (27/29), (2)
being able to stop taking HIV medications permanently (24/
29), (3) not having to think about having the virus (22/29), (4)
not being at risk of the diseases and conditions that often go
along with HIV or are worsened by it (22/29), and (5) having
a better quality of life (20/29) (Fig. 2). One woman wrote that
‘‘putting away the stigma that comes with the status’’ would
most positively affect her life.
Table 1. Demographic Characteristics of AIDS
Clinical Trials Group 5366 Female Respondents
at Entry Visit (n = 29)
Demographic characteristicsa n (%)
Race
Black or African American 18 (62.1)
White 10 (34.5)
American Indian or Alaska Native 1 (3.4)
Ethnicity
Hispanic or Latina 25 (86.2)
Not Hispanic or Latina 4 (13.8)
Education
Less than high school 7 (24.1)
High school or general education
development/diploma
4 (13.8)
Some college (less than 2 years) 8 (27.6)
Associate degree or more than 2 years of
college
5 (17.2)
Undergraduate degree or equivalent 4 (13.8)
Professional degree (e.g., Master’s degree or
equivalent)
1 (3.4)
Doctorate degree or equivalent terminal degree 0 (0)
Current marital status
Single, never married 7 (24.1)
Married, without children 1 (3.4)




Did not answer 1 (3.4)
Yearly household income (in US dollars)




More than $100,000 1 (3.4)
Sources of money or support to cover basic living and other
expensesb
Regular, full-time job 7 (18.9)
Regular, part-time job 5 (13.5)
Temporary work 1 (2.7)
Help from family, partners or friends 5 (13.5)
Some form of government support 14 (37.8)
Otherc 3 (8.1)
Refuse to answer 2 (5.4)
aDemographic data for exit survey completers not shown.
bCategories are not mutually exclusive, so percentages add up to
more than 100%.
c‘‘Other’’ included three respondents with Social Security Income
or work pension.
FIG. 1. Self-assessment of
current health status at entry
visit (n = 26).
FIG. 2. Attributes of a possible future HIV cure/remission that would most positively affect lives of ACTG 5366 female
participants (n = 29). ACTG, AIDS Clinical Trials Group.
Motivators of participation in ACTG 5366
Primary reason for enrollment. Participants were asked
for the primary reason they decided to participate in the study at
the entry visit. Over two-thirds (21/29) wrote an answer related
to altruism or helping find a cure for HIV. Representative
quotes included: ‘‘the primary reason I decided to participate in
this study is to help see if certain medicines will help re-
searchers with a cure for the disease,’’ ‘‘to serve as a participant
and to enable the process towards finding a cure that will help
others be liberated from this deadly virus,’’ ‘‘I decided because
I want to be an example for other people that [who] are living
with [this] virus that there is research and medicine out there
that can help them get better,’’ ‘‘to help provide data to further
cure,’’ ‘‘helping science and contributing to studies,’’ and ‘‘to
help my community.’’ Interestingly, 2/29 women wrote about
their desire to be cured of HIV (e.g., ‘‘to be cured’’ and ‘‘be-
cause I wanted a cure’’). Additional responses related to hope
for cure, medical care, and ensuring representation of women
in research (e.g., ‘‘to hope for a cure,’’ ‘‘because they [re-
searchers] care more about my health’’ and ‘‘not enough wo-
men to do them [studies]’’). With respect to decision-making
around enrollment, most (23/29) women discussed their par-
ticipation with at least one other person, including HIV care
provider or HIV care team and family members.
Satisfaction with informed consent. All but one partici-
pant indicated that they were satisfied with the informed
consent process. When asked to specify why they were sat-
isfied with the informed consent process, respondents wrote:
‘‘the study and the consent were explained so that I under-
stood,’’ ‘‘because the consent is very thorough so I can un-
derstand the study,’’ ‘‘[the] doctor explained [the] study
thoroughly and that made me feel that I was not in danger,’’
‘‘the information appears to have a clear plan to cure the
virus,’’ and ‘‘the nurse was very specific.’’
Understanding of the ACTG 5366 Study
Main purpose of study. At the entry visit, we asked ACTG
5366 participants to describe the main purpose of the study
using free text responses. (The study purpose was described as
follows in the ACTG 5366 informed consent form: ‘‘Re-
searchers will study whether these two medications [vorinostat
and tamoxifen] given together are safe and tolerable. Re-
searchers will also look at whether the two drugs work better
together in waking up the latent virus in women than vorinostat
given alone.’’) Over two-thirds (22/30) of participants de-
scribed the study as helping advance HIV cure-related science.
Some participants had a rather sophisticated understanding of
the study. For example: ‘‘to see if estrogen receptor can awa-
ken the latent virus in the reservoirs allowing medications to
act on stopping its replication,’’ ‘‘to find out if a) latent cells
can be woken up and b) if one drug can work equally well as
two drugs,’’ and ‘‘[t]o help researchers find a cure to HIV by
connecting or combining two medications and seeing their
response together in clearing the virus.’’ A minority (4/29) of
participants described ACTG 5366 as searching for positive
results leading to a better treatment or cure for HIV.
Four true/false questions were used to clarify study un-
derstanding (Fig. 3). All women (29/29) correctly understood
that the study produced knowledge that may be used one day
to develop new therapies to cure or control HIV. The majority
(25/29) accurately recognized that they were being randomly
assigned to a study group. Close to two-thirds (19/29) cor-
rectly answered that there may be gender/sex differences in
how people respond to HIV treatment. More than half (17/29)
responded ‘‘true’’ to the statement that study was meant to
benefit their personal health (Fig. 3).
Details about study agents. Women were asked to de-
scribe the study drugs, vorinostat, and tamoxifen. 6/29 wo-
men identified vorinostat as a latency reversal agent, and 14/
FIG. 3. Responses from ACTG 5366 participants related to the understanding of the study at entry visit (n = 29).
29 alluded to its use in cancer treatment, including breast
cancer. Tamoxifen was described by 3/29 as a female hor-
mone receptor modulator, by 3/29 as helping vorinostat wake
up latent virus, and by 15/29 as a treatment of cancer.
However, 4/29 were unsure about the purpose of the vor-
inostat and 2/29 about the purpose of tamoxifen. Only 1/29
incorrectly described tamoxifen as the latency reversal agent.
Perceptions of risks and benefits
Identified risks and benefits. When ACTG 5366 study
participants were asked at entry about risks of participating in
the study, 6/29 women responded that there was no risk in-
volved, 21/29 responded that there were risks involved, and
2/29 did not know. When asked to specify risks, 11 free text
responses submitted included possible side effects. One
woman indicated that she did know the specific risks. When
asked if there were any benefits of participating in the study,
the majority of women responded ‘‘yes’’ (24/29), while 4/29
responded ‘‘no,’’ and 1/29 responded ‘‘don’t know.’’ In free
text responses to specify the benefits, 11 women referred to
helping find a cure for HIV, 3 referred to possible health
benefits, and 1 referred to the psychological benefits. Five
women identified compensation as helping with their par-
ticipation and two women wrote that the study might cure
them as a benefit (Table 2).
The entry survey included more structured, close-ended
questions around perceived benefits and risks of being in the
Table 2. Responses from AIDS Clinical Trials Group 5366 Participants Around Perceived
Risks and Benefits of Study at Entry
Themes Quotes received
Are there any risks to participating in this study?
Side effects (11 responses)  ‘‘Possibility of having side effects’’
 ‘‘Possible side effects of the medication’’
 ‘‘Could experience some side effects’’
 ‘‘Possible side effects’’
 ‘‘The medications have some side effects’’
 ‘‘Side effects of drugs’’
 ‘‘The side effects form the study medications’’
 ‘‘Possible Secondary Effects’’
 ‘‘Symptoms from the meds’’
 ‘‘A reaction to the drugs’’
 ‘‘Drug can make me nauseous and I can get bruises from punctures’’
Other responses (5 responses)  ‘‘There is a risk for everything’’
 ‘‘There are minimal risk to all studies’’
 ‘‘I don’t know how it is going to work’’
 ‘‘You may and or may not qualify’’
 ‘‘Always’’
Don’t know what risks are (n = 1)  ‘‘I don’t know what they are’’
Are there any benefits to participating in this study?
Helping find a cure for HIV (11 responses)  ‘‘Helping finding a cure’’
 ‘‘Help find a cure’’
 ‘‘May find a cure for HIV’’
 ‘‘Finding a cure for AIDS and HIV’’
 ‘‘To find possible HIV cure’’
 ‘‘Finding a cure to HIV & AIDS’’
 ‘‘Finding a cure for AIDS and HIV’’
 ‘‘It enables me to look anxiously to a cure’’
 ‘‘Help others’’
 ‘‘Learn if this combo helps flush HIV out of reservoirs’’
 ‘‘The virus that is hiding in my body will be destroyed, even
if it’s just for a while’’
Health benefits (3 responses)  ‘‘Living a healthier life. Live longer’’
 ‘‘Medical Evaluations and Laboratory [Test Results]’’
 ‘‘My health doing well’’
Psychological benefits (1 response)  ‘‘Psychological’’
Compensation (1 response)  ‘‘Compensation’’
Mixed responses (4 responses)  ‘‘Adding to science and the $25 compensation’’
 ‘‘Yes your time is not wasted (.) you are being apart of something
that can insure life’’
 ‘‘To see how the medication effects the virus and compensation’’
 ‘‘It can help researchers find answers and compensation cards’’
Other or miscellaneous (1 response)  ‘‘There might be’’
Cure for HIV (2 responses)  ‘‘May be cured’’
 ‘‘It maybe cure’’ [sic]
study. The three most prevalent perceived social benefits of
the study were (1) moving one step closer to finding a cure for
HIV (29/29), (2) helping the HIV community (29/29), and (3)
helping other women living with HIV (29/29) (Fig. 4). When
asked about perceived personal benefits, the three most
prevalent answers were (1) feeling good about contributing to
HIV cure research (29/29), (2) receiving updated information
about HIV (28/29), and (3) benefiting from the best medical
care (26/29) (Fig. 5). The three most prevalent social risks of
being in the study included: (1) having a cure for HIV that is
not available to those who need it (7/29), (2) other people
finding out about study participation and HIV-positive status
(5/29), and (3) being recognized as someone living with HIV
(3/29) (Fig. 6). When asked about perceived personal risks,
the three most prevalent answers were (1) possible permanent
or irreversible side effects (6/29), (2) HIV reactivation inside
the body (5/29), and (3) large blood draws needed for the
study (4/29) (Fig. 7).
FIG. 4. Perceived social benefits of the ACTG 5366 study at entry visit (n = 29).
FIG. 5. Perceived personal benefits of the ACTG 5366 study at entry visit (n = 29).
FIG. 6. Perceived social risks of the ACTG 5366 study at entry visit (n = 29).
FIG. 7. Perceived personal risks of the ACTG 5366 study at entry visit (n = 29). 
Self-image and perceived stigma
In addition to the open-ended and structured questions
around motivators of participation, ACTG 5366 participants
were specifically asked whether negative feelings about HIV
influenced their decision to participate in the study. Over a
quarter (8/29) said that negative feelings played a role in their
decision to join the study. Explanations included: ‘‘I am tired
of feeling alone,’’ ‘‘[it’s] not easy to explain,’’ ‘‘I hate this
disease,’’ ‘‘the stigma has been toxic to me’’ and ‘‘I hate
living with the virus and it played a role in me participating in
the study.’’ With regard to external stigma, 21/29 agreed or
strongly agreed that they were very careful about disclosure
of their HIV diagnosis (Fig. 8). With regard to internal stig-
ma, 13/29 agreed or strongly agreed that they were hiding
their HIV seropositive status, 12/29 agreed or strongly agreed
that having HIV was like being branded with shame, and 12/
29 felt blemished (Fig. 9).
Role of compensation for ACTG 5366 clinical trial
The entry survey concluded by asking women about the
role of compensation in joining the ACTG 5366 clinical
study. When asked if they were offered compensation, 17/29
said ‘‘yes’’ and described compensation as money, gift cards,
or parking, 9/29 said ‘‘no,’’ and 3/29 did not know. Of the 15
women who responded to the question ‘‘Do you feel this
FIG. 8. Perceptions of external stigma for ACTG 5366 study participants at entry visit (n = 29).
FIG. 9. Perceptions of internal stigma for ACTG 5366 study participants at entry visit (n = 29).
compensation is sufficient?,’’ 11/15 said ‘‘yes,’’ explaining
‘‘fair for time involved,’’ ‘‘covers the basics,’’ and ‘‘it’s en-
ough’’ and 4/15 said ‘‘no’’ with reasons including ‘‘time is
worth more,’’ ‘‘the visits are quite long and travel expenses
are expensive,’’ and ‘‘incentive is small compared to other
studies.’’
When asked about the importance of compensation 10/17
disagreed and 7/17 agreed that reimbursements/study sti-
pends facilitated their participation in the study by defraying
some of the costs and time associated with their involvement
with the trial. Reasons for disagreeing with the statement
included: ‘‘I didn’t join because of money,’’ ‘‘it’s not enough
money to make me join a study, but it’s appreciated’’ and
‘‘the evaluations are more important.’’ Reasons for agreeing
with the statement were the following: ‘‘might help me to pay
for my parking, cab fare, getting me to the doctor,’’ ‘‘park-
ing,’’ ‘‘it helps me pay for some bills and transportation.’’ We
also asked ACTG 5366 participants if they considered re-
imbursements to be a potential benefit of the clinical study.
Of the 28 women who responded, 24/28 said ‘‘yes’’ indi-
cating ‘‘it’s nice to be paid for your time and travel to clinic’’
and ‘‘it’s a way of showing respect.’’
Exit surveys
At the end of the study, 27 women completed the exit
survey (demographic data not shown). All but one replied
that they would recommend the study to others. Re-
presentative statements given for recommending the study to
others included: ‘‘no bad experience during the course of the
study,’’ ‘‘this study was easy to do with little side effects,’’
‘‘did not require anything invasive,’’ ‘‘because when you join
you learn so many things that can help with having HIV,’’
‘‘because we don’t have enough women doing research with
HIV,’’ ‘‘be part of something greater than self,’’ and ‘‘every
opportunity to advance medical science is a wonderful op-
portunity for [the] human condition.’’
When asked if the study would provide information that is
important to advancing the field of HIV cure-related re-
search, 22/27 strongly agreed. Perceived benefit categories
included feeling good about contributing to science, health
benefits, gaining knowledge, compensation, and other mixed
responses (Table 3).
Women were asked if they would be willing to volunteer
for another similar study in the future and all (n = 27) an-
swered ‘‘yes.’’ One woman explained as follows: ‘‘I have
not lost anything by participating but the science may have
gained information toward a cure.’’ Using structured ques-
tions, we asked about problems related to participation in the
study. 24/27 did not report any problem. However, 2/27
reported finding HIV cure-related research very compli-
cated to understand, 2/27 felt stigma from participating in
the study, 1/27 reported parking problems, and 1/27 reported
‘‘Other—too much blood at each visit.’’ Finally, we asked
participants if they felt valued as study participants. 25/27
answered ‘‘yes,’’ 1/27 answered ‘‘no,’’ and 1/27 answered
‘‘don’t know.’’
Discussion
Our findings provide unique insights into the perspectives
of women enrolled in a single multisite small trial conducted
across the United States, who have been traditionally un-
derrepresented in HIV research.3 To our knowledge, this is
the first study to examine how women living with HIV per-
ceived and experienced participation in such a study. The
nested social science surveys yielded a rich dataset examin-
ing the experiences of people living with HIV in cure-related
Table 3. Perceived Benefits from AIDS Clinical Trials Group 5366 Study Respondents
at the End of the Study
Themes Quotes received
Did you benefit from participating in this study?
Feeling good about contributing
to science (5 responses)
 ‘‘I feel like I’ve helped the researchers learn more about HIV and anything
they can learn is a direct to me’’
 ‘‘Hopefully help science move along’’
 ‘‘Because I helped out others which made me feel good’’
 ‘‘It gave me an immense satisfaction that I was given an opportunity
to be part of this study’’
 ‘‘Because helping research with medications needed for HIV’’
Health benefits (3 responses)  ‘‘Getting medication for my health to make my health better’’
 ‘‘I was monitored closely’’
 ‘‘For me to know what’s going on in my body (.)’’
Gaining knowledge (3 responses)  ‘‘Gained knowledge’’
 ‘‘I learned more about reservoirs than I knew before’’
 ‘‘It was a learning tool for me’’
Compensation (2 responses)  ‘‘I benefited from the gift cards’’
 ‘‘Yeah got extra cash’’
Mixed responses (3 responses)  ‘‘Getting my labs performed and receiving the test results. Learning about
different medications. Taught me discipline about taking my HIV meds’’
 ‘‘My benefit is not just the money it is helping to find a cure, giving my blood
to help I find to be a good thing besides I was put here to help’’
 ‘‘Medical follow-up, laboratory tests and treatment that can benefit [others]’’
Other or miscellaneous (1 response)  ‘‘Yes, I do feel I’ve benefited from this study’’
research.18–20 We identified societal and personal motivators
for participation, understanding of risks and benefits, and
some misconceptions in a minority of trial participants. Al-
most all women had a very positive experience participating
in the ACTG 5366 trial, and would recommend the study to
others. Using these findings could help in the design, im-
plementation, recruitment, and retention of women in HIV
cure-related research, highlighting the value of assessing
psychosocial and affective factors in HIV cure-related re-
search participation. Importantly, our study showed the fea-
sibility of integrating participant-centered outcomes, here an
assessment of how needs of participants were met, in an in-
tensive multi-site HIV cure-related interventional trial.
Our findings strengthen the proposition that a thorough
examination of how participants perceive and experience
HIV cure-related research has ethical significance.18 Re-
search teams are responsible for ensuring participants un-
derstand the nature of early-phase research: namely, that
scientific findings are incremental, and that studies will not
be curative. Trial teams should also be attentive to partici-
pants’ needs throughout the study.15,22 Participants them-
selves can provide unique insights into the best way to
optimize their trial experience while minimizing harms,
including social harms.
The surveys uncovered a host of reasons why ACTG 5366
participants decided to join the study. These included a mix
of societal and altruistic reasons around helping find a cure
for HIV, combined with the desire to personally benefit and
improve one’s health. The desire to help advance science,
combined with the need for personal benefits mirrors those
found previously in the HIV cure18,19,23 and other fields (e.g.,
HIV prevention24 or oncology25,26). Almost all respondents
indicated that they were satisfied with the informed consent
process and understood the study as helping advance HIV
cure-related science. Some showed a sophisticated under-
standing of the study and its purpose. However, we noted
misunderstandings in a minority of participants (e.g., the
belief that tamoxifen was the latency-reversing agent).
Interestingly, a small subset of women seemed to believe
that the ACTG 5366 study could potentially cure them,
despite that the ACTG 5366 informed consent form avoi-
ded the use of the word ‘‘cure.’’ Scholars have discouraged
the use of the word ‘‘cure’’ entirely in study-related doc-
uments to avoid participant misconceptions about the po-
tential for cure from these early-phase investigations.17,27
Using terms that more precisely describe the mechanisms
being studied (e.g., latency reversal) can go a long way in
setting realistic expectations28–30 but can also at times be
overly technical. Biomedical HIV cure research teams must
also ensure adequate comprehension from study partici-
pants to ensure they are joining studies for appropriate
reasons.31 Others have suggested increasing the readability
of informed consent forms,29 and using decision-making
checklists.32 Undoubtedly, biomedical HIV cure research
teams should appreciate the psychological dimensions of
HIV cure-related research participation.19,27 As bioethi-
cists have previously posited, it is possible that partici-
pants’ seemingly high expectations of clinical benefits may
simply have reflected their hopes.26,33
The surveys also revealed general understanding of the
associated risks and benefits, but some lack of recall about
specific details. Over two-thirds recognized that there were
risks involved, but most had difficulty naming specific clin-
ical risks. The ACTG 5366 informed consent form contained
three pages detailing the possible risks of the study, including
the risks of vorinostat and tamoxifen, risks of nonstudy
medications, risks of drawing blood, risks of electrocardio-
gram, risks of social harms, risks of stored samples, and risks
of future study participation. Our finding that participants had
difficulty recalling specific clinical risks seems consistent
with previous sociobehavioral research.20,29 This finding
further raises the question of whether risk information should
be simplified or participants should be engaged in a discus-
sion about risks during follow-up study visits.
Notably, over half believed that the study would benefit
their personal health and the majority emphasized the like-
lihood of societal and personal (e.g., health and psychologi-
cal) benefits. However, the ACTG 5366 informed consent
form clearly stated that participants would ‘‘receive no ben-
efit from being in this study.’’ This apparent contradiction has
been witnessed elsewhere,18,20 and has led scholars to ad-
vocate for ethics committees and biomedical research teams
to take inclusion benefits into account.34–36 Some intangible
benefits identified by participants included a sense of con-
tributing to science and more frequent evaluation in clinical
settings. The topic of altruistic benefits, such as feeling good
about helping advance HIV cure-related science, emerged
prominently throughout the survey responses for almost all
ACTG 5366 study participants. This finding parallels similar
sociobehavioral research where stated altruism was the most
commonly cited reason for joining HIV cure-related stud-
ies.19,20,37,38 Given the early-phase nature of the ACTG 5366
study, participation should rest principally on altruism and
aspirational societal benefits.39 Fostering a healthy sense of
altruism and responsibly emphasizing societal benefits may
facilitate HIV cure research participation.38 From an ethical
standpoint, however, altruistic outlook should not unduly
distort risk perceptions for experimental interventions, par-
ticularly in ‘‘otherwise healthy volunteers’’ who may have
more to lose.40,41
Importantly, survey findings revealed the pervasive role
of stigma in women’s lives, and in decisions to join HIV
cure-related studies, even for very healthy women living
with HIV. This finding aligns with focus groups conducted
in the United States where participants strongly valued the
possible destigmatizing effect of no longer having HIV.42
Once again, more research is needed to better understand
how stigma and self-image may act as motivators or bar-
riers to HIV cure-related research participation, particu-
larly for women.43
Reimbursement for the time involved in research partici-
pation appears to have played a role in decisions to partici-
pate. For at least one-third of women, reimbursements
facilitated their participation in the study. Furthermore, the
majority perceived reimbursements as a benefit of being in
the study. This finding is ethically relevant, since IRBs do not
recognize compensation as a benefit.44–46 While ethics
committees do not generally recognize compensation as a
benefit, and research teams do not present reimbursements as
benefits, it is possible that study participants still genuinely
perceive them as such. Stipends to defray the costs of study
participation may play an important role in motivating par-
ticipants, women in particular, and in helping them overcome
barriers to research participation.
Table 4. Summary of Findings and Possible Implications for HIV Cure-Related Research
Themes Possible implications
Decisions to participate in research  HIV cure researchers should recognize that people living
with HIV may join trials for a variety of reasons.
 ACTG 5366 participants joined the study for a
combination of reasons, including societal and altruistic
benefits of contributing to science, and the desire to
personally benefit.
 People living with HIV, and women in particular, may
need to consult with important people in their lives before
making decisions to participate.
Understanding of the study  The word ‘‘cure’’ should be avoided in all study-related
documents. Precise terms that describe study mechanisms
may go a long way in setting realistic expectations.
 Most ACTG 5366 participants understood the study as
helping advance HIV cure-related science. Some
women showed a sophisticated understanding of the
study.
 Biomedical HIV cure researchers should ensure adequate
comprehension of study participants. This may require
repeated communication during study follow-up.
 Over half thought the study would personally benefit
their personal health.
 Increasing the readability of informed consent forms or
using informed decision-making checklists could be
helpful in enhancing understanding.
 We noted minor misunderstandings about the study in a
subset of participants.
 The psychological aspects of research participation should
be appreciated. Study participants should also be provided
with adequate psychological counseling and support.
 A small number believed the study could possibly result
in a cure.
 Ascertaining the existence of therapeutic or curative
misconception requires in-depth probing of study
participations.
 Further empirical research is needed to examine how
participants understand various HIV cure studies and
interventions.
Perceptions of risks and benefits  Biomedical HIV cure research teams should simplify risk
information during the informed consent process, and
provide refreshers during study visits.
 The majority of ACTG 5366 participants understood
that some risks were involved, but had difficulty naming
specific clinical risks.
 Biomedical HIV cure research teams should ascribe value
to the lived experiences of study participants. This is
particularly important for research involving women.
 ACTG 5366 participants valued the likelihood of health
and psychological benefits, while the informed consent
form emphasized there would be no direct benefit.
 Attention should be paid to how risks and benefits are
communicated to study participants.
 Information should be collected on how participants
perceive and understand risks and benefits of research,
with the close involvement of social scientists in a multi-
disciplinary research effort.
 Biomedical HIV cure research teams should emphasize the
incremental nature of scientific discovery and that initial
studies will not be curative.
 While biomedical HIV cure research teams can explain to
participants that they will be closely monitored, it should
be emphasized that experimental study interventions are
not meant to benefit participants’s health directly, but to
advance biomedical science.
Meaning of the study and altruism  Biomedical HIV cure research teams should foster a
healthy sense of altruism, while ensuring altruistic outlook
does not unduly distort risk perceptions.
 Several ACTG 5366 participants gave altruistic reasons
for joining the study. These altruistic motivations were
also mixed with the desire for personal benefit.
 Future HIV cure studies should explore how participants
weigh various motivations—including altruistic intentions
versus self-oriented motivations.
 In-depth empirical research is needed to precisely
characterize the type of altruism witnessed in HIV cure-
related study participants.
Self-image and perceived stigma  Biomedical HIV cure research teams should appreciate
that, despite being otherwise healthy, participants may still
need to cope with various layers of stigma in daily life.
 Stigma remains a pervasive reality in the lives of several
women who volunteered for the ACTG 5366 study, and
appears to have played a role in decisions to join the
study.
 More research is needed to better understand the role of
stigma and self-image in decisions to participate or stay
involved in research.
(continued)
At the end of the study, we were surprised and encouraged
to find such high satisfaction from the ACTG 5366 partici-
pants. Almost all women stated that they would recommend
the study to others and would volunteer for another similar
study in the future. The majority believed the information
gained would advance the field of HIV cure-related research
and endorsed benefiting from the study. The very few prob-
lems experienced included finding HIV cure-related research
difficult to understand, feeling stigma, parking problems, and
having too much blood drawn.
A major strength of our study is the collection of participant-
centered data at two critical time points: entry and exit. None-
theless, we must acknowledge a number of limitations. The
baseline survey was administered *1 month after enrollment
and informed consent, and may have been subject to recall bias.
We did not collect participant reports longitudinally throughout
the study and may have missed fluctuations in attitudes better
captured by real-time assessments. We also focused on specific
domains of inquiry using semistructured surveys, which may
not have conveyed the richness of meaning, variations in re-
sponses, and uniqueness of participant’s experiences that would
be provided by in-depth interviewing. Further, we did not sur-
vey those who chose not to enroll in the study nor assess their
reasons for refusing to participate in the ACTG 5366 study.16
Since participants had to be postmenopausal and ‘‘otherwise
healthy volunteers,’’ data may not generalize to all women
living with HIV in the United States or in other settings. We also
do not have a comparable study of men for comparison and
cannot determine if features of the participant’s experiences are
unique to women or shared. Future studies should collect more
in-depth psychological characteristics of study participants to
obtain a more complete picture of health. These shortcomings
notwithstanding, we believe that our findings have high internal
validity and add to the literature of women’s participation in
HIV cure-related research.
Table 4 includes a summary of key findings and possible
implications for HIV cure-related research.
Conclusion
In sum, the ACTG 5366 trial was the first women-only
HIV cure-related protocol implemented in the United States.
The study showed that it is possible to recruit and retain
women in HIV cure-related research, and to embed
participant-centered outcomes at strategic time points during
the study. Our study identified societal and personal moti-
vators for participation, understanding of risks and benefits,
and minor misconceptions in some trial participants. Results
point to the need for continued engagement and clarification
of participant expectations throughout the entire course of
trial implementation. Given the paucity of similar prospec-
tively collected data from participants in HIV cure-related
trials, further work will be needed to identify features specific
to women, particularly for studies involving HIV treatment
interruptions. Careful inclusion of women in HIV cure-
related research studies, combined with sex/gender-based
analyses, will also be crucial for the design of interventions
that are efficacious in and acceptable for all people living
with HIV.12 Ensuring representation of women in HIV re-
search will remain a fundamental issue of equity and jus-
tice.47 Our research underscores the feasibility of a robust and
multidisciplinary HIV cure research agenda to examine
participant values, perceptions, and lived experiences.48,49
Together with meaningful community and stakeholder en-
gagement, monitoring participants’ psychosocial experiences
will be crucial to understand, from their points of view, the
factors that will enhance the acceptability of interventions.
As the biomedical sciences continue to evolve toward an HIV
cure, it will be critical to appreciate both the biomedical and
the sociobehavioral dimensions of this research enterprise.
Ultimately, to develop medical products that are patient-
centered, we will need to encourage a framework of research
that centers around participants, and what they consider to be
most meaningful.
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